{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae XL HCG"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K131037",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003178"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHA"
    ],
    "Summary Letter Date": "September 6, 2013",
    "Summary Letter Received Date": "August 21, 2013",
    "Submission Date": "August 14, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human chorionic gonadotropin (HCG) test system"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Human chorionic gonadotropin (hCG)",
        "Beta-hCG"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae XL HCG chemiluminescent immunoassay for quantitative determination of hCG in human serum for early pregnancy detection.",
    "Indications for Use Summary": "Quantitative determination of total human chorionic gonadotropin (hCG and \u03b2hCG) in human serum for early detection of pregnancy using the LIAISON\u00ae XL Analyzer.",
    "fda_folder": "Clinical Chemistry"
}